164 related articles for article (PubMed ID: 1659595)
41. Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia.
Gotti E; Suter F; Baruzzo S; Perani V; Moioli F; Remuzzi G
Clin Transplant; 1996 Dec; 10(6 Pt 1):550-5. PubMed ID: 8996777
[TBL] [Abstract][Full Text] [Related]
42. Management of cytomegalovirus infection.
Meyers JD
Am J Med; 1988 Aug; 85(2A):102-6. PubMed ID: 2841853
[TBL] [Abstract][Full Text] [Related]
43. Gastrointestinal cytomegalovirus infection in heart and heart-lung transplant recipients.
Kaplan CS; Petersen EA; Icenogle TB; Copeland JG; Villar HV; Sampliner R; Minnich L; Ray CG
Arch Intern Med; 1989 Sep; 149(9):2095-100. PubMed ID: 2549896
[TBL] [Abstract][Full Text] [Related]
44. Resistance to combined ganciclovir and foscarnet therapy in a liver transplant recipient with possible dual-strain cytomegalovirus coinfection.
Rodriguez J; Casper K; Smallwood G; Stieber A; Fasola C; Lehneman J; Heffron T
Liver Transpl; 2007 Oct; 13(10):1396-400. PubMed ID: 17902124
[TBL] [Abstract][Full Text] [Related]
45. Cytomegalovirus infection in renal transplant recipients.
Carstens J; Andersen HK; Spencer E; Madsen M
Transpl Infect Dis; 2006 Dec; 8(4):203-12. PubMed ID: 17116133
[TBL] [Abstract][Full Text] [Related]
46. Positive pretransplantation cytomegalovirus serology is a risk factor for cardiac allograft vasculopathy in children.
Hussain T; Burch M; Fenton MJ; Whitmore PM; Rees P; Elliott M; Aurora P
Circulation; 2007 Apr; 115(13):1798-805. PubMed ID: 17353448
[TBL] [Abstract][Full Text] [Related]
47. Clinical course of cytomegalovirus (CMV) viremia with and without ganciclovir treatment in CMV-seropositive kidney transplant recipients. Longitudinal follow-up of CMV pp65 antigenemia assay.
Yang CW; Kim YO; Kim YS; Kim SY; Moon IS; Ahn HJ; Koh YB; Bang BK
Am J Nephrol; 1998; 18(5):373-8. PubMed ID: 9730559
[TBL] [Abstract][Full Text] [Related]
48. Practices for cytomegalovirus diagnosis, prophylaxis and treatment in allogeneic bone marrow transplant recipients: a report from the Working Party for Infectious Diseases of the EBMT.
Ljungman P; De Bock R; Cordonnier C; Einsele H; Engelhard D; Grundy J; Locasciulli A; Reusser P; Ribaud P
Bone Marrow Transplant; 1993 Oct; 12(4):399-403. PubMed ID: 8275040
[TBL] [Abstract][Full Text] [Related]
49. Cytomegalovirus as a cause of very late interstitial pneumonia after bone marrow transplantation.
de Medeiros CR; Moreira VA; Pasquini R
Bone Marrow Transplant; 2000 Aug; 26(4):443-4. PubMed ID: 10982292
[TBL] [Abstract][Full Text] [Related]
50. Ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients: a single-center retrospective cohort study.
Young PG; Rubin J; Angarone M; Flaherty J; Penugonda S; Stosor V; Ison MG
Transpl Infect Dis; 2016 Jun; 18(3):390-5. PubMed ID: 27037651
[TBL] [Abstract][Full Text] [Related]
51. Aerosol administration of antiviral agents to treat lung infection due to murine cytomegalovirus.
Debs RJ; Montgomery AB; Brunette EN; DeBruin M; Shanley JD
J Infect Dis; 1988 Feb; 157(2):327-31. PubMed ID: 2826613
[TBL] [Abstract][Full Text] [Related]
52. New developments in cytomegalovirus prevention and management.
Snydman DR; Rubin RH; Werner BG
Am J Kidney Dis; 1993 Feb; 21(2):217-28. PubMed ID: 8381578
[TBL] [Abstract][Full Text] [Related]
53. Cytomegalovirus pneumonia in adult autologous blood and marrow transplant recipients.
Konoplev S; Champlin RE; Giralt S; Ueno NT; Khouri I; Raad I; Rolston K; Jacobson K; Tarrand J; Luna M; Nguyen Q; Whimbey E
Bone Marrow Transplant; 2001 Apr; 27(8):877-81. PubMed ID: 11477447
[TBL] [Abstract][Full Text] [Related]
54. Phase I-II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients.
Reusser P; Gambertoglio JG; Lilleby K; Meyers JD
J Infect Dis; 1992 Sep; 166(3):473-9. PubMed ID: 1323614
[TBL] [Abstract][Full Text] [Related]
55. Long-term outcomes of cytomegalovirus infection and disease after lung or heart-lung transplantation with a delayed ganciclovir regimen.
Thomas LD; Milstone AP; Miller GG; Loyd JE; Stephen Dummer J
Clin Transplant; 2009; 23(4):476-83. PubMed ID: 19453645
[TBL] [Abstract][Full Text] [Related]
56. Cytomegalovirus infection after bone marrow transplantation: relation of pneumonia to postgrafting immunosuppressive treatment.
Skinhøj P; Andersen HK; Møller J; Jacobsen N
J Med Virol; 1984; 14(2):91-9. PubMed ID: 6092531
[TBL] [Abstract][Full Text] [Related]
57. Delay of CMV infection in high-risk CMV mismatch lung transplant recipients due to prophylaxis with oral ganciclovir.
Palmer SM; Grinnan DC; Diane Reams B; Steele MP; Messier RH; Duane Davis R
Clin Transplant; 2004 Apr; 18(2):179-85. PubMed ID: 15016133
[TBL] [Abstract][Full Text] [Related]
58. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients.
Winston DJ; Busuttil RW
Transplantation; 2003 Jan; 75(2):229-33. PubMed ID: 12548129
[TBL] [Abstract][Full Text] [Related]
59. Ganciclovir and hyperimmunoglobulin for treating cytomegalovirus infection in bone marrow transplant recipients.
Aulitzky WE; Tilg H; Niederwieser D; Hackl M; Meister B; Huber C
J Infect Dis; 1988 Aug; 158(2):488-9. PubMed ID: 2841384
[No Abstract] [Full Text] [Related]
60. Efficacy of a 6-week prophylactic ganciclovir regimen and the role of serial cytomegalovirus antibody testing in lung transplant recipients.
Kelly JL; Albert RK; Wood DE; Raghu G
Transplantation; 1995 Apr; 59(8):1144-7. PubMed ID: 7732561
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
